Tohoku University

Zenoaq Resource Co., Ltd.

Other

Zenogen Pharma Co., Ltd.

Mika Kato

Yukinari Kato

Satoshi Ogasawara

Shinji Yamada

Takuro Nakamura

The present invention provides a cancer cell-specific anti-podoplanin antibody or an antigen-binding fragment thereof having an epitope in a Thr85-containing region of an amino acid sequence of human podoplanin represented by SEQ ID NO: 1, the Thr85 having a sialylated O-glycan added thereto.

Anti-podoplanin antibody

The present invention provides a cancer microenvironment-targeting anti-podocalyxin antibody or antigen binding fragment thereof.

Anti-podocalyxin antibody that targets tumor microenvironment

Object of the present invention is to provide various anti-podoplanin antibodies useful as a drug or reagent. The present invention provides an anti-podoplanin antibody or antigen-binding fragment thereof, each having an epitope in any of the following regions in the amino acid sequence of podoplanin represented by SEQ ID NO: 1: (i) from position 56 to position 80, (ii) from position 81 to position 103, (iii) from position 81 to position 88, and (iv) from position 25 to position 57.

Growing community of inventors

Miyagi, Japan

Mika Kato